Bladder Cancer - Results from #660

REVIEW UroToday

Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. January 3, 2024

Predictors of response to neoadjuvant therapy in urothelial cancer. January 3, 2024

Metabolomic Signatures of Treatment Response in Bladder Cancer. January 2, 2024

Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer. January 2, 2024

PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. January 1, 2024

Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma. January 1, 2024

Significance of Normalized Apparent Diffusion Coefficient in the Vesical Imaging-Reporting and Data System for Diagnosing Muscle-Invasive Bladder Cancer. December 29, 2023

Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial. December 29, 2023

Development and validation of a novel nomogram model for predicting the survival of patients with T2-4a, N0-x, M0 bladder cancer: a retrospective cohort study. December 28, 2023

Differentiation of bladder cancer with water flow elastography (WaFE). December 28, 2023

OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway. December 27, 2023

Health Related Quality of Life in Patients with Bladder Cancer Receiving a Radical Cystectomy. December 27, 2023

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. December 26, 2023

HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer. December 26, 2023

Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis. December 25, 2023

The Use of Hospital Services by Patients With Muscle Invasive Bladder Cancer in the Last Year of Life: Identifying the Areas to Improve Care. December 25, 2023

Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study. December 22, 2023

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer. December 22, 2023

Pangea Laboratory Receives FDA Breakthrough Device Designation for the Bladder CARE™ Assay December 21, 2023

Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer. December 21, 2023

Page 34 of 517